Search Results

Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating

Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies Sosei

function and drug discovery of GPCR signaling Illuminating the understudied GPCR-ome Industry News Sosei

GPCR Therapeutics' latest science paper was published by the American College of Clinical Pharmacology Sosei

Sosei Heptares Confirms Changes to its Board and Executive Management Team at Annual Shareholders’ Meeting

Therapeutics was nominated for the Trophée de l'Innovation Technologique (Technological Innovation Award) Sosei

Kevin Wright Joins GPCR Therapeutics as Director of Targeted and Immuno-oncology Sosei Heptares Adds

Facility with Hercules Capital Gene-to-structure and Europe give Proteros customers a winning hand Sosei

Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for

spearhead global development and North American expansion as the leading GPCR immuno-oncology company Sosei

Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine Platform Sosei

GPCR-Gi protein complex Deep Learning Dynamic Allostery of G-Protein-Coupled Receptors Industry News Sosei

Science Offerings with Multispan Cell Engineering and Assay Services $3bn sales potential for drug Sosei

Fourth Quarter And Full Year 2022 Financial Results And Provides Corporate Update Alastair Brown from Sosei

Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 Sosei

progress its proprietary CCR8 antibody candidate to the clinic Novo strikes another obesity drug deal Sosei

Industry News The Adrenaline Puzzle Solved: Scientists Untangle Key Cell Receptor's Inner Workings Sosei

Obesity: Likelihood of Approval Septerna to Participate in Upcoming Investor and Industry Conferences Sosei

Pharmaceuticals gets grant for patent granted for somatostatin modulators for treating hormone-related conditions Sosei

Medicines for CNS Diseases Addex Reports Full Year 2022 Financial Results and Provides Corporate Update Sosei